We are studying the safety and effectiveness of quizartinib combined with chemotherapy in children and adolescents newly diagnosed with FLT3-ITD positive acute myeloid leukemia. This trial aims to see if it helps improve treatment outcomes compared to standard therapies.
Health conditions and diseases that the clinical trial is designed to study and treat.
Pediatric Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow in children. It is characterized by the presence of specific genetic mutations, such as FLT3-ITD positivity and NPM1 wild-type status, leading to the rapid growth of abnormal white blood cells.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
